Partial
Mostly Aligned
Patient Risk:
Low
Summary
Three of four claims align with the label (strengths and a common 150 mg twice-daily regimen). One claim (60 capsules per month) is not supported by the label. Notable safety-related omissions are present (contraindications, boxed warnings, pregnancy/pediatric use) beyond the claims evaluated.
Category Scores
Accurate Statements
Pradaxa (dabigatran etexilate) is a prescription anticoagulant.
Indications and Usage describe conditions requiring anticoagulation and dosing for AF, DVT, PE, which implies anticoagulant use; however the label text provided does not explicitly state the descriptor 'anticoagulant'.
Pradaxa dosage options include 75 mg, 110 mg, and 150 mg.
3 DOSAGE FORMS AND STRENGTHS lists 75 mg, 110 mg, and 150 mg capsule strengths.
A common regimen is 150 mg twice daily.
2.2 Recommended PRADAXA Capsules Dosage for Adults lists 150 mg twice daily for indications such as reduction in stroke/systemic embolism risk in non-valvular AF and treatment of DVT/PE.
Unsupported Statements
That regimen equates to 60 capsules per month.
The label provides daily dosing but does not specify a monthly capsule count.
Contradictions
Important Omissions
No explicit contraindications, boxed warnings, pregnancy/pediatric use information, or other safety warnings mentioned in the claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Safety elements are not addressed in the claims; potential risk if used improperly due to missing contraindications/boxed warnings.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omission of safety cautions (contraindications, boxed warnings, pregnancy/pediatric use) and a monthly capsule count
Suggested Improvement
Add explicit safety sections and administration details, and avoid implying a monthly capsule count without labeling support.